TRIM32

Across TCGA pan-cancer cohorts, TRIM32 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TRIM32 data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher TRIM32 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TRIM32 expression acts as an unfavorable survival marker.

LIHC, LUAD, and STAD are the cancer types where TRIM32 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.059	0.775	<.001	24	view →
LUAD	DFS	Median	All	0.178	0.813	<.001	15	view →
STAD	OS	Median	III,IV	0.184	0.641	.011	9	view →
COAD	DFS	Median	All	0.162	0.696	.001	9	view →
LUSC	DFS	Median	II,III,IV	0.199	0.748	.006	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TRIM32–LIHC (OS)

Open the LIHC breakdown →